News | July 15, 2025
Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
To streamline complex medical writing workflows with GenAI
It is intended for contrast enhancement in MRI scans
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
The company showcased three core programs developed through this platform
Subscribe To Our Newsletter & Stay Updated
